
AI-powered antibody Fc engineering platform for next-gen biologics
Built from URLSee something off about this company?
Developing biotherapeutics with optimized efficacy, safety, and manufacturability is slow and costly, with high downstream failure rates due to poor translation from computational design to clinical reality.